Key Takeaways
- Weather wiped out Q2, but H1 held up: Revenue fell to ₹930 crores from ₹988 crores YoY as unseasonal rains stopped spraying, yet H1 still delivered 9% sales growth and 11% profit growth with no returns or price cuts.
- Margins proved resilient in a stress test: Gross margins held at 43.1% and H1 EBITDA margin at 22% despite the volume shock, while working capital days improved by 7 days YoY.
- The innovation pipeline is accelerating: India is now a #1 category for Sumitomo Japan's global molecule testing, two new molecules are already in trial, and Dahej greenfield will anchor manufacturing for the next decade.
- Cash pile has a destination, not a distribution: ₹2,089 crores of cash will fund Dahej capex and other opportunities under evaluation; management explicitly ruled out returning it to shareholders.
- What to watch next quarter: Whether Rabi demand recovery materializes on healthy reservoir levels, the pace of Excalia Max and Lentigo scaling, and any Board approval for Dahej projects before year-end.
Weather Impact & Demand Recovery
- The Q2 shock: First 18 days of July were dry, then rain started 19th July and continued through September, preventing farmers from spraying agrochemicals. Volume contraction drove the entire revenue decline; price realization stayed broadly stable.
- H1 resilience: Despite the Q2 washout, H1 grew 9% in sales and 11% in profit. No goods were returned, no prices were reduced, and profitability was maintained throughout the adverse conditions.
- Rabi setup looks favorable: Healthy reservoir levels, adequate soil moisture and normal monsoon withdrawal have improved field conditions significantly since late September, creating a constructive base for Rabi season demand.
- Channel discipline held: Very little sales return materialized; farmer meetings and channel engagement helped liquidate inventory. However, the inventory level sitting with competitors in the market is unknown.
- Domestic growth philosophy: Management acknowledged low-single-digit domestic sales CAGR over three years looks subpar versus peers, but called it intentional: the primary aim is maintaining or improving margins through a specialty-heavy mix and disciplined order processing, with no dumping and no supply without firm orders. Top line comes after that.
Chetan Shah: "I must admit that today, I was hoping to join you all with a very, very robust Q2 working on the basis of what we did in Q1. However, I think the God and the nature had some different plans of their own."
New Product Launches & Innovation Pipeline
- Excalia Max and Lentigo: Both launched pan-India in June-July. Excalia Max is a patented fungicide using INDIFLIN technical sourced from Sumitomo Japan; Lentigo is a rice herbicide. Management says both are surpassing initial estimates, though it declined to disclose revenue figures, calling it too early at three months post-launch.
- Other product traction: Meshi is on track to cross 5 lakh liters against a 10 lakh liter target. Mera 71 sold 3,000 tonnes in H1 versus a previous full-year best of 2,800 tonnes. CTPR, launched last year with in-house manufacturing, is doing well in the off-patent division.
- India elevated to #1 testing category: Sumitomo Chemical Japan has placed Sumitomo Chemical India alongside North America, Brazil and Japan as a priority geography for testing new discovery molecules. Previously, India would only be considered 2-5 years after initial launch in those markets. Two molecules have already been received for testing.
- Top Grain launch planned: A product from Valent BioSciences is scheduled for launch in H2 FY26.
- Every Day Farmers Day: The direct farmer outreach initiative running since 2024 has become a key differentiator, enabling product demonstrations and brand recall enhancement. Plans are to expand coverage across additional districts with more focus on Rabi crops.
Chetan Shah: "India has been put or Sumitomo Chemical India has been put by Japan as a #1 category for testing new molecules."
Manufacturing & Capex
- Dahej greenfield: Land acquisition and environmental approvals are complete; feasibility studies for seven products have been submitted. Two product clearances are already received, with the balance five expected by end of this financial year. Implementation timelines are 18 months to 2 years post-approval, so some projects should start generating revenue sometime in calendar year 2028. The site will primarily cater to domestic business with additional capacity used for exports, and has potential to support growth for the next 10-12 years.
- Bhavnagar expansion: Full commercialization of the first phase (₹120 crores) is achieved. A second phase (₹55 crores new capex) will double capacities at the site for a product made for the parent company.
- Tarapur site evolution: Originally planned as a fully export-oriented multiproduct site, part of its capacity is now used for domestic requirements including CTPR. Going forward, Tarapur will be an equal mix of exports and domestic, even after new products start production in two years. A pilot plant for Excalia Max TG is being completed here, after which India-sourced TG can serve the domestic market without Japanese imports.
- Backward integration: Commenced for selected molecules at the Tarapur facility.
- Cash deployment: The ₹2,089 crores cash balance will be partly consumed by Dahej capex. Management is also evaluating various options to fast-track and accelerate deployment, including opportunities beyond agrochemicals, but no decisions have been made. There are no plans to return capital to shareholders.
Kunal Mittal: "We expect that during this current financial year, some of these projects should go and get approved both by our parent company and us and our Board. And once they get approved, we will take these projects to the implementation at the ground level, with implementation time lines of 18 months to 2 years. So maybe sometime in calendar year 2028, we see that some of these projects should start generating revenues."
Exports & Global Markets
- Regional divergence: Africa and Latin America saw shipment deferrals, with one key molecule in Brazil carrying inventory that is now liquidating, pushing shipments from H1 to H2. The US and Europe remained stable. Africa's season should start towards end of December or early January, and the market situation there seems okay. Latin American customers are described as positive despite channel pressure. The US outlook depends on the tariff situation.
- China competitiveness: Management stated that due to R&D efforts and process improvements, costs have been reduced enough to compete with Chinese prices across all generic products exported. Prices are believed to be at or near the bottom.
- Export profitability: Margins on exports are at the same level as the last 2-3 years and have not eroded.
- Global stabilization signs: The agrochemical industry is witnessing early signs of stabilization after nearly two years of inventory destocking, pricing pressure and climate disruptions. Ordering patterns are gradually normalizing and prices appear to have bottomed out in key markets.
Chetan Shah: "In spite of the very steep competition from China, due to our R&D efforts and process improvements, we have saved a lot of cost in order to compete with the Chinese prices. And I'm glad to inform that in all the products that we export as generic products, we are in a position to compete China."
Segment Performance
| Segment | Trend | Commentary |
|---|---|---|
| Domestic Crop Protection | ▼ Q2 hit | Key brands Sumimax, Excalia Max, Lentigo and older herbicides gained traction despite weather; volume was the casualty, not brand strength. |
| Environmental Health | ▲ Healthy growth | Growing presence in branded solutions and urban vector control, off a low base. |
| Exports | ▬ Mixed | Africa and LatAm deferred; US and Europe stable. H2 recovery expected as deferred shipments materialize. |
| Barrix Agro Sciences | ▬ Steady top line | Revenue broadly in line with previous year; profitability hit by higher input costs, elevated opex, and a regulatory disruption that blocked biostimulant sales from mid-June to late September. |
| Specialty vs Generic mix | ▲ Structural shift | Specialty has grown from 22-24% of portfolio to 28-30% over five years. In H1 it dipped 1%, but management believes the structural growth trajectory remains intact. |
Margins, Pricing & Financial Discipline
- Margin resilience: Gross margins held at 43.1% in Q2. H1 EBITDA margin was 22%, broadly in line with expectations despite the adverse seasonal impact. Management stated efforts are to maintain or improve EBITDA margin and profit before tax; these will not go down.
- Pricing discipline proved: Prices were successfully maintained even in the challenging Kharif conditions. Management sees no reason to lower prices in the future even if volumes rise, and believes prices are at the bottom.
- Working capital improvement: Net working capital days improved by 7 days YoY to 55 days, driven by better receivable collections and stable inventory management. The company is committed to sustaining this momentum through stringent credit control and optimized inventory levels.
- Domestic margin philosophy: The deliberate focus on high-margin products and specialty mix, combined with disciplined order processing, is designed to protect margins. Top-line growth is secondary to margin maintenance in the stated strategy.
Chetan Shah: "The prices are definitely sustainable. As a matter of fact, if prices had to be lower, it was in this particular condition, a tough condition of Kharif. We have successfully maintained the price line even in these challenging months, I don't see any reason for us to lock the prices in the future."
Parent Company Relationship & Adjacent Opportunities
- Japan's decision-making pace: Management acknowledged that dealing with Japan is very sustainable but speed can be slower than expected, and some delays or frustrations stem from the Japanese working style. This is relevant context for Dahej approval timelines and new molecule flow.
- Adjacent segments under evaluation: Opportunities in the parent company's other businesses (display materials, pharma, semiconductor) are being evaluated for India. Each business will make its own independent decision, and there is no legal obligation for these to come into the listed entity. Management's endeavor is to convince Japan to route them through Sumitomo Chemical India Limited, but many segments may not have readily available Indian opportunities yet.
- Semiconductor timeline: The semiconductor business will take more time, linked to when key players' plants in India start operations. The company is in touch with all customers including Tata and monitoring the ground-level situation. The offering will be a mix of imported products and some localized in India.
Chetan Shah: "Dealing with Japan as a country, it is very, very sustainable, but the speed can be lesser than what we expect it to be. So a little bit of delays or a little bit of this thing which we feel frustration about is due to the working style of Japan, basically, I would say that."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Rabi demand recovery | Capitalize on healthy reservoir levels and improved field conditions to drive volume growth | Rabi season (H2 FY26) |
| Dahej project approvals | Some of the 7 projects to get parent and Board approval; 18-24 month implementation follows | During current financial year (FY26) |
| Dahej revenue generation | Some projects to start generating revenue | Calendar year 2028 |
| Excalia Max TG localization | Pilot plant at Tarapur being completed; thereafter no need to import TG from Japan | Not specified |
| Top Grain launch | Product from Valent BioSciences to launch | H2 FY26 |
| EBITDA margin | Maintain or improve; will not go down | Ongoing |
| Cash deployment | Fund Dahej capex; evaluate other opportunities; no return to shareholders | Ongoing |
| Barrix sales restart | Looking to start sales as soon as possible after regulatory disruption | Not specified |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹930 cr, down from ₹988 cr in Q2 FY25 |
| H1 FY26 revenue | ₹1,987 cr, up 9% YoY from ₹1,827 cr |
| Gross margin | 43.1%, vs 42.6% in Q2 FY25 |
| EBITDA | ₹218 cr, vs ₹245 cr in Q2 FY25 |
| EBITDA margin | 23.4%, vs 24.8% in Q2 FY25 |
| Profit after tax | ₹178 cr, vs ₹193 cr in Q2 FY25 |
| PAT margin | 19.1%, vs 19.5% in Q2 FY25 |
| H1 FY26 EBITDA margin | 22.0%, vs 22.2% in H1 FY25 |
| H1 FY26 PAT | ₹356 cr, up 11% YoY |
| Domestic business growth (H1 FY26) | 11% YoY, contributing 85% of revenue |
| Export revenue growth (H1 FY26) | -4% YoY; South America down 33% |
| Net working capital days | 55 days, improved by 7 days YoY |
| Cash and cash equivalents | ₹2,089 cr as of 30 Sep 2025 |
| H1 FY26 collections | ~₹2,277 cr, vs ₹1,999 cr in H1 FY25 |
| New product contribution | 8% to 10% of revenue on a yearly basis |